ReviewNeurobiology of learning and memory2020
Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.
Review in Neurobiology of learning and memory, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 64 citations in OpenAlex.
- Dorsolateral Prefrontal Cortex Circuitry at the Intersection of Cognition and Disease.Biological psychiatry · 2026Review
- Article
- Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry.Biological psychiatry · 2026Review
- Dynamic modeling in neurocognitive frameworks of childhood ADHD: a review of inhibitory control and reward systems.Translational psychiatry · 2026Review
- Beyond dopamine: Broader neuromodulatory contributions in sign- and goal-tracking.Psychopharmacology · 2026Review
- Article
- ADHD treatments move beyond stimulants.Nature · 2026Article
- Effects of atomoxetine and methylphenidate on quality of life and self-esteem in adults with ADHD.Frontiers in psychiatry · 2026Article
- Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice.eNeuro · 2026Article
- Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder.Frontiers in molecular neuroscience · 2026Review
- Oral guanfacine treatment ameliorates the ADHD-like symptoms caused by developmental manganese exposure.Progress in neuro-psychopharmacology & biological psychiatry · 2025Article
- Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan.BMC psychiatry · 2025Article
- Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Ibudilast-Mediated Suppression of Neuronal TLR4 in the Prefrontal Cortex Mitigates Methamphetamine-Induced Neuroinflammation and Addictive Behaviours.Addiction biology · 2025Article
- Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder.Children (Basel, Switzerland) · 2025Article
- A stratified precision medicine trial targeting αNature. Mental health · 2025Article
- A novel multimodal pharmacologic approach using guanfacine, N-acetylcysteine, and donepezil in severe TBI: a case series.Frontiers in rehabilitation sciences · 2025Article
- Chemogenetic tools for modulation of spatial learning in dopamine transporter deficient rats.Frontiers in neuroscience · 2025Article
- Efficacy and safety of guanfacine in hospitalized patients with delirium: A scoping review.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Article
- Neurobiology of attention-deficit hyperactivity disorder: historical challenges and emerging frontiers.Nature reviews. Neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selective norepinephrine (NE) α2A-adrenoceptor (α2A-AR) agonist, guanfacine (Intuniv™), is FDA-approved for treating Attention Deficit Hyperactivity Disorder (ADHD) based on research in animals, a translational success story. Guanfacine is also widely used off-label in additional mental disorders that involve impaired functioning of the prefrontal cortex (PFC), including stress-related disorders such as substance abuse, schizotypic cognitive deficits, and traumatic brain injury. The PFC subserves high order cognitive and executive functions including working memory, abstract reasoning, insight and judgment, and top-down control of attention, action and emotion. These abilities arise from PFC microcircuits with extensive recurrent excitation through NMDAR synapses. There is powerful modulation of these synapses, where cAMP-PKA opening of nearby potassium (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.